SCHEMBL2365802

SCHEMBL2365802

COCC1COC(=O)N1c1ccc(C(=O)N2CCN(c3ncc(C)cc3C)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.41
CFTR P13569 1/20 0.39
ALDH1A1 P00352 5/20 0.38
PIK3CA P42336 1/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MGLL Q99685 1/20 0.36
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
TSHR P16473 1/20 0.36
P2RX3 P56373 1/20 0.36
P2RX2 Q9UBL9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365795 1.00 LMNA (0.41) LMNACFTRALDH1A1PIK3CAMAPT
SCHEMBL2365905 0.92 LMNA (0.39) LMNACFTRALDH1A1MAPTKDM4E
SCHEMBL2365894 0.92 LMNA (0.39) LMNACFTRALDH1A1MAPTKDM4E
SCHEMBL2366732 0.91 ALDH1A1 (0.40) LMNAALDH1A1KDM4EPOLBKMT2A
SCHEMBL2366739 0.91 ALDH1A1 (0.40) LMNAALDH1A1KDM4EPOLBKMT2A
SCHEMBL2366152 0.91 LMNA (0.40) LMNAALDH1A1PIK3CAMAPTKDM4E
SCHEMBL2366146 0.91 LMNA (0.40) LMNAALDH1A1PIK3CAMAPTKDM4E
SCHEMBL2366574 0.90 P2RX3 (0.44) LMNAALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL2366568 0.90 P2RX3 (0.44) LMNAALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL2366652 0.90 LMNA (0.39) LMNAALDH1A1PIK3CAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 LMNA 3668/4885CFTR 1831/4885ALDH1A1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.